<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01464216</url>
  </required_header>
  <id_info>
    <org_study_id>REK-2010/1656</org_study_id>
    <nct_id>NCT01464216</nct_id>
  </id_info>
  <brief_title>MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness</brief_title>
  <acronym>FuncProst</acronym>
  <official_title>MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to combine and correlate data from morphological and functional&#xD;
      MRI, molecular signatures of tumor hypoxia, the presence of micrometastases and tumor hypoxia&#xD;
      with the goal being predicting of prostate cancer aggressiveness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective study including 180 consecutive patients with PCa referred to Oslo University&#xD;
      Hospital, Radiumhospitalet, for surgical treatment. In vivo functional MRI examination will&#xD;
      be performed within a few days prior to robot-assisted radical prostatectomy (RALP). For a&#xD;
      subgroup of patients FACBC PET will also be acquired prior to prostatectomy. A subgroup of&#xD;
      intermediate and high-risk patients (D'Amico risk classification) will prior to surgery&#xD;
      receive an intravenous infusion of the hypoxia-marker pimonidazole (Hypoxyprobe™-1)*. During&#xD;
      surgery, bone marrow aspiration and blood collection will be performed for assessment of&#xD;
      disseminated and circulating tumor cells. High-risk patients will undergo intraoperative&#xD;
      lymph node dissection. Tumor tissue for molecular analyses will be sampled from prostate&#xD;
      specimen prior to fixation. Prostate specimen and regional lymph nodes will be&#xD;
      histopathologically examined for T- and N-classification, Gleason grade, presence of&#xD;
      micrometastasis and areas of hypoxia. Histological and molecular findings will be correlated&#xD;
      to MRI and PET findings and clinical data. Patients will be longitudinally followed to assess&#xD;
      long-time clinical outcome (recurrence, metastatic disease, death).&#xD;
&#xD;
      *From 2013 oral administration is used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>2030</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Genital Neoplasms, Male</condition>
  <condition>Prostatic Diseases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, bone marrow, lymph nodes, prostate tissue, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prostate cancer patients referred for surgical treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suitable for surgery with confirmed prostate cancer, Gleason grade ≥ 3&#xD;
&#xD;
          -  Patient has received no prior treatment for prostate cancer.&#xD;
&#xD;
          -  Patient has adequate renal function: Estimated creatinine clearance ≥ 60 ml/minute.&#xD;
&#xD;
          -  Patient must sign written informed consent according to the protocol approved by the&#xD;
             Regional Ethics Committee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with contraindication to MR or MR contrast media according to clinical&#xD;
             practice.&#xD;
&#xD;
          -  Patients who want to withdraw for any reason during the study.&#xD;
&#xD;
          -  Patients previously undergone pelvic surgery or radiation therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Therese Seierstad, PhD, MHA</last_name>
    <email>therese@radium.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese Seierstad, phD</last_name>
      <phone>+4746451987</phone>
      <email>Therese.Seierstad@rr-research.no</email>
    </contact>
    <investigator>
      <last_name>Therese Seierstad, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Knut Håkon Hole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karol Axcrona, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>October 31, 2011</study_first_submitted>
  <study_first_submitted_qc>November 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2011</study_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Therese Seierstad</investigator_full_name>
    <investigator_title>Head of Research, Department of Radiology and Nuclear Medicine</investigator_title>
  </responsible_party>
  <keyword>Functional Magnetic Resonance Imaging</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>FACBC PET</keyword>
  <keyword>Hypoxia imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Male</mesh_term>
    <mesh_term>Prostatic Diseases</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

